Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $42.60 USD
Change Today +0.60 / 1.43%
Volume 564.5K
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$41.88
Previous Close
$42.00
Day High
$42.99
Day Low
$41.79
52 Week High
03/4/15 - $50.98
52 Week Low
10/9/14 - $16.13
Market Cap
4.7B
Average Volume 10 Days
1.2M
EPS TTM
$-1.57
Shares Outstanding
109.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Senior Vice President of Health Sector
Total Annual Compensation: $986.0K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

intrexon corp (XON) Key Developments

Intrexon Seeks Acquisitions

Intrexon Corporation (NYSE:XON) will consider acquisitions. We continue to track to our ambitious expectations," commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon. "As the benefits of our technology platforms and business model accumulate, we expect to continue to drive operating and financial performance in such a way as to produce excellent capital efficiency, which will allow us to grow both organically and by acquisition.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Results Ended March 31, 2015

Intrexon Corporation announced unaudited consolidated earnings results for the first quarter results ended March 31, 2015. For the quarter, the company reported total revenues of $3,849,000 against $7,854,000 a year ago. Operating loss was $87,123,000 against $17,872,000 a year ago. Income before income taxes was $26,599,000 against $3,555,000 a year ago. Net income attributable to Intrexon was $27,097,000 against $4,115,000 a year ago. Net income per share, diluted was $0.25 against $0.04 a year ago. EBITDA was $31,663,000 against $6,218,000 a year ago. Adjusted LBITDA was $11,309,000 against adjusted EBITDA of $17,585,000 a year ago. Adjusted LBITDA per diluted share was $0.11 against adjusted EBITDA per diluted share of $0.18 a year ago.

Intrexon Declares Special Stock Dividend, Date of Distribution Will Occur in Mid-June 2015

Intrexon’s Board of Directors declared a special stock dividend of 17,830,305 shares of ZIOPHARM common stock owned by Intrexon to its shareholders. The distribution of the special stock dividend will be made on the Distribution Date to all Intrexon shareholders of record on June 4, 2015. The date of distribution by Intrexon of the special stock dividend is contemplated to occur in mid-June 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $42.60 USD +0.60

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $171.94 USD +3.37
Photon Technology International Inc $0.0001 USD 0.00
MorphoSys AG €68.90 EUR +0.418
XOMA Corp $3.42 USD +0.025
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.2x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.